What is Pembrolizumab Intravenous
Pembrolizumab intravenous is a prescription medication used to treat certain types of cancer. It belongs to a group of medications called monoclonal antibodies. Pembrolizumab works by blocking the activity of a protein called PD-1. This may help the body’s immune system attack the cancer cells.
Pembrolizumab is available as an injection (liquid) that is given by a healthcare provider into the vein.
Benefits of Pembrolizumab Intravenous
and Its Uses.
Pembrolizumab intravenous is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Pembrolizumab is used to treat certain types of cancer, including melanoma and non-small cell lung cancer.
Pembrolizumab is often given after other cancer treatments have failed.
Pembrolizumab may also be used for purposes not listed in this medication guide.
Pembrolizumab is a monoclonal antibody that blocks the action of PD-1.
PD-1 is a protein found on the surface of immune cells called T cells.
When PD-1 is blocked, T cells are more likely to attack and destroy cancer cells.
Pembrolizumab is given as an infusion into a vein.
Pembrolizumab is usually given every 3 weeks.
Your doctor will determine how long
Side Effects and Dosage of Pembrolizumab Intravenous
Pembrolizumab (trade name Keytruda) is a monoclonal antibody used in cancer therapy. It is used to treat a number of different types of cancer, including melanoma, non-small cell lung cancer, and head and neck cancer. It is a humanized antibody that binds to the PD-1 receptor on T cells, preventing the receptor from signalling the T cell to die.
Pembrolizumab is given as an intravenous infusion. The recommended dose for melanoma is 2 mg/kg every three weeks. For non-small cell lung cancer, the recommended dose is 200 mg every three weeks. For head and neck cancer, the recommended dose is 200 mg every two weeks.
Pembrolizumab can cause a number of side effects, including fatigue, nausea, diarrhea, rash, and decreased appetite. It can also cause infusion-related reactions, including fever, chills, and shortness of breath.